Abecma (idecabtagene vicleucel) / BMS - LARVOL DELTA

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (ASH 2025) - P2 | "10/43 (23%) had ≥1 prior BCMA-directed therapies (BCMA-DT) (4 bela-maf, 2cilta-cel, 6 ide-cel)...3/3 pts with PD who received talquetamab (Tal) as next therapyresponded (2 VGPR, 1 CR)... In this preliminary analysis, discontinuation of Tec after 6-9m yields outcomes comparableto historical expectations with continuous therapy with estimated median FFS of 73% at 12m post-discontinuation in a cohort with 23% prior BCMA-DT. Early instances of PD (<6m after Tecdiscontinuation) that were evaluable exhibited BCMA loss and were thus unlikely due to Tecdiscontinuation. Response to Tal immediately after failing Tec re-treatment and low sBCMA at PD furthersuggest resistance due to BCMA loss/mutation as an important mechanism of PD even months after Tecdiscontinuation."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • SDC1

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the "STEM" (Sequential T Cell-Engagement for Myeloma) trial (ASH 2025) - P2 | "Median number of prior lines was 4 (2-10), with 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab. Twenty-five (93%) received cilta-cel and 2 (7%) ide-cel... To date, cevostamab consolidation starting 10-12 weeks post-CAR T cell infusion at 3.6mgsingle step-up and 132mg q3wk target dose appears feasible and well-tolerated in heavily-pretreatedRRMM, with low rates of non-hematologic G3/4 TEAE's, including infections. Preliminary efficacy appearspromising, with over 90% showing sustained MRD-negative CR at 1 year. Analyses and follow-up areongoing."

CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • Ataxia • Autoimmune Hepatitis • Cough • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Movement Disorders • Multiple Myeloma • Musculoskeletal Pain • Neutropenia • Respiratory Diseases • Thrombocytopenia

Efficacy of idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma with prior central nervous system involvement: a multicenter real-world analysis (DKK 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

D-Domain Binder In Anitocabtagene Autoleucel Shows Absence of Tonic Signaling and Cross-Reactivity Profile (TCT-ASTCT-CIBMTR 2026) - "This profile differentiation may be attributed to the different BCMA-targeting binders, as current standard-of-care BCMA-directed CAR-T cell therapies either demonstrate suboptimal durability of response with idecabtagene vicleucel (ide-cel), or a risk of delayed toxicities with ciltacabtagene autoleucel (cilta-cel). Off-target activity with dual VHH CAR-T cells was seen with CLDN9, suggesting that the high avidity dual VHH binder could lead to off-tumor binding as CLDN9 is expressed in tight junctions across various tissues (Higashi et al., Sci Rep 2021). Other features of the D-Domain previously reported such as fast off-rate and lack of self-aggregation may contribute to enhanced target specificity and lack of tonic signaling, differentiating it from the dual VHH binder. Further studies are ongoing and additional data will be included if selected."

IO biomarker • Late-breaking abstract • CNS Disorders • Gastrointestinal Disorder • Hematological Malignancies • Movement Disorders • Multiple Myeloma • Parkinson's Disease • CD69 • FAS • IFNG

CIBMTR Real-World Comparison of Ide-Cel and Cilta-Cel In relapsed/refractory Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "In this largest real-world comparison to date, cilta-cel showed deeper responses and improved PFS/OS but was associated with more delayed neurotoxicity—highlighting the need for optimized patient selection and proactive risk mitigation strategies."

Clinical • Real-world • Real-world evidence • CNS Disorders • Hematological Malignancies • Movement Disorders • Multiple Myeloma • Parkinson's Disease

Optimizing Fludarabine: The Impact of Fludarabine Renal Dose Adjustment during Lymphodepletion Prior to CAR-T cell Immunotherapy in Multiple Myeloma Patients (TCT-ASTCT-CIBMTR 2026) - "Background: Fludarabine and cyclophosphamide form the standard lymphodepletion regimen for chimeric antigen receptor (CAR) T-cell therapy, including ciltacabtagene autoleucel and idecabtagene vicleucel, in relapsed or refractory multiple myeloma (RRMM). Maintaining full-dose fludarabine for patients with CrCl 50–69 mL/min did not increase toxicity, while those with CrCl 30–49 mL/min receiving reduced doses maintained efficacy. These findings support institutional dosing practices and demonstrate comparable safety and efficacy across renal function groups. 1 ."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Renal Disease • Thrombocytopenia

Cardiac Toxicities Following Chimeric Antigen T-cell Therapy: A Post-Marketing Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System (TCT-ASTCT-CIBMTR 2026) - " CAEs from FAERS database prior to March 2025 were identified for Tisagenlecleucel (Tisa-cel), Axicabtagene ciloleucel (Axi-cel), Lisocabtagene maraleucel (Liso-cel), Brexucabtagene autoleucel (Brexu- cel), Idecabtagene vicleucel (Ide-cel), and Ciltacabtagene autoleucel (Cilta-cel). This post-marketing pharmacovigilance analysis highlights patterns of cardiac AEs following CAR-T therapy. Though limited by FAERS reporting bias, trends of CAEs with CAR-T support the ongoing need for patient counseling, optimization of cardiac comorbidities, early recognition of new events, and timely interventions. Characterize the spectrum and patterns of cardiac adverse events seen with CAR-T therapy."

Adverse events • P4 data • Acute Coronary Syndrome • Acute Lymphocytic Leukemia • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Heart Failure • Hematological Malignancies • Hypotension • Leukemia • Lymphoma • Multiple Myeloma • Myocardial Infarction

Survival after Chimeric Antigen Receptor T-cell Therapy Is Predicted By Fried's Frailty Phenotype (TCT-ASTCT-CIBMTR 2026) - "Idecabtagene vicleucel (n=12), tisagenlecleucel (n=12) and ciltacabtagene autoleucel (n=11) were the most frequently administered products. Future studies to reverse frailty with exercise interventions and to uncover the biologic mechanisms of frailty's association with adverse disease outcomes may lead to novel targets for intervention. -To determine the proportion of patients receiving CART who are frail, prefrail or fit by Fried's phenotype -To determine whether there is an association between CART toxicity and Fried's phenotype -To determine whether frailty by Fried's phenotype is associated with overall survival"

CAR T-Cell Therapy • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma

Establishing an Outpatient CAR-T Therapy Program in an Infusion Center (TCT-ASTCT-CIBMTR 2026) - "Initial eligibility included age <65 years, ECOG 0–1, Karnofsky ≥70, and treatment with Kymriah or Breyanzi...In February 2025, Yescarta was added, and a pilot removed age limits, admitting patients on Day +1; following five uneventful cases, this practice became standard. The next step, planned for November 2025, is outpatient Abecma infusion with same-day admission to mitigate early CRS risk...Identify patient selection criteria and phased implementation strategies that support safe outpatient CAR-T administration. Evaluate the clinical and operational outcomes of an outpatient CAR-T program, including patient experience, safety, and resource utilization."

Clinical • Hematological Malignancies

Improving Handoff Communication in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-cell Therapy (TCT-ASTCT-CIBMTR 2026) - "Methods, Intervention, & Analysis This QI project included MM patients treated with ide-cel or cilta-cel and referred from community oncology practices. Nurses ensure clear, targeted information exchange that promotes adherence to infectious prophylaxis and IVIG protocols, reducing infection risks and improving outcomes. By customizing handoff tools and coordinating care, nurses enhance communication effectiveness and patient safety in oncology practice."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Real World CAR-T cell Therapy Outcomes in RR/MM with and without Cardiac Co-Morbidities: A Propensity Matched Database Study (TCT-ASTCT-CIBMTR 2026) - "Introduction Pivotal trials such as CARTITUDE-1 and KarMMa that established the efficacy of ciltacabtagene autoleucel (ide-cel) and idecabtagene vicleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM) excluded patients with cardiac co-morbidities like pre-existing severe heart failure, severe cardiomyopathies or ventricular arrhythmias. 3 . Determine if cardiac conditions affect CAR-T therapy effectiveness or safety."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Inflammation • Multiple Myeloma • Neutropenia • Obesity • Oncology • Thrombocytopenia

Outcomes of Idecabtagene Vicleucel in relapsed/refractory Multiple Myeloma across Racial and Ethnic Groups: Real-World Evidence from the CIBMTR (TCT-ASTCT-CIBMTR 2026) - "3 . To generate evidence that informs equitable clinical decision-making and promotes diversity and representation in future CAR T-cell therapy trials and real-world practice."

Clinical • HEOR • Real-world • Real-world evidence • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Thrombocytopenia

Outcomes of CAR-T in relapsed/refractory Myeloma with Severe Renal Dysfunction: A Propensity-Matched Analysis (TCT-ASTCT-CIBMTR 2026) - "Introduction: Two BCMA CAR-T therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), are approved for relapsed/refractory multiple myeloma (RRMM). CAR-T therapy yields comparable efficacy and safety in RRMM patients with renal failure, supporting inclusion of this cohort in CAR-T eligibility. Identify if CAR-T in relapsed/refractory multiple myeloma has different outcomes in renal insufficiency Identify if CAR-T in relapsed/refractory multiple myeloma has different toxicities in renal insufficiency Identify factors that affect these outcomes"

Cardiovascular • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Nephrology • Neutropenia • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombocytopenia

Impact of Baseline and Dynamic IMWG Simplified Frailty Scores on Outcomes after CAR T-cell and Bispecific Antibody Therapy in Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "We evaluated how baseline and dynamic frailty influence efficacy and toxicity among MM patients treated with CAR T- cell (ide-cel, cilta-cel) and bispecific antibody (teclistamab [tec], talquetamab [tal]) tx. Both fit and frail pts benefit from cellular therapies and are important therapeutic options for pts across all fitness categories. However, further work is required to understand impact on depth and durability of response. Ultra-frail pts durability of response and depth of response merits further investigation in a large cohort of MM pt."

CAR T-Cell Therapy • Geriatric Disorders • Hematological Malignancies • Multiple Myeloma

Infections in Patients with Relapsed Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy: A Real-World Analysis from CIBMTR (TCT-ASTCT-CIBMTR 2026) - "The study results demonstrate a significant incidence of infections for a prolonged duration (14.1% in the first 30 days and 27% in the first 100 days) in patients undergoing ide-cel therapy. Viral infections increased beyond d+30 and multiple infections (≥2 episodes) were associated with inferior OS. 1."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Comparative Outcomes of Idecabtagene Vicleucel in Relapse and Refractory Multiple Myeloma Patients with and without Prior BCMA Therapy: A CIBMTR Real-World Analysis (TCT-ASTCT-CIBMTR 2026) - "3 . To translate real-world evidence into clinical insight—informing treatment sequencing, patient selection, and optimizing CAR T-cell therapy outcomes in advanced multiple myeloma."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Thrombocytopenia

Day 90 NGS-Based MRD Negativity Predicts Survival after BCMA-Directed CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma. (TCT-ASTCT-CIBMTR 2026) - " We retrospectively analyzed 171 MM patients treated with idecabtagene vicleucel (110/171) and ciltacabtagene autoleucel (cilta-cel), at Moffitt Cancer Center from May 2021 - September 2024 who had D90 NGS-MRD testing (<1 in 10 5 cells). In this large cohort of MM patients, D90 NGS-MRD(-) was independently associated with improved PFS and OS. Our data support the use of D90 NGS-MRD testing as a prognostic tool for survival outcomes and the development of MRD-driven interventions post CAR-T. To evaluate differences in baseline characteristics of patients achieving MRD negativity vs not after standard of care BCMA-directed therapy To evaluate the prognostic impact of Day 90 NGS-MRD on progression free survival To identify independent effect of MRD status on survival among other associated variables of survival"

CAR T-Cell Therapy • IO biomarker • Minimal residual disease • Next-generation sequencing • Hematological Malignancies • Multiple Myeloma

Influence of CAR-T Product Selection on Survival and Acute Toxicities in Multiple Myeloma: A Real-World Comparative Study (TCT-ASTCT-CIBMTR 2026) - "3 . Identify key risks to guide treatment choices between ide-cel and cilta-cel."

Clinical • Real-world • Real-world evidence • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Inflammation • Multiple Myeloma • Neutropenia • Obesity • Respiratory Diseases • Thrombocytopenia

The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma (TCT-ASTCT-CIBMTR 2026) - " Pts receiving cilta-cel (n=71) or ide-cel (n=50) were analyzed. Higher albumin is associated with response, while lower albumin with NRM. Despite global NLR declines after infusion, very low NLR paradoxically associates with earlier progression, suggesting a complex immune recovery pattern. Results presented merit further exploration of albumin and NLR in larger cohorts of CAR-T pts."

Biomarker • Clinical • IO biomarker • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Real-World Outcomes of Idecabtagene Vicleucel in relapsed/refractory Multiple Myeloma: Comparative Analysis of Genetically and Clinically Defined High-Risk Versus Standard-Risk Patients from the CIBMTR Registry (TCT-ASTCT-CIBMTR 2026) - "3 . To generate data-driven insights that refine future patient selection, guide treatment sequencing, and inform next-generation CAR T and bispecific strategies for high-risk multiple myeloma."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Thrombocytopenia

Parkinsonism Post BCMA-Directed CAR-T Therapy in Multiple Myeloma Patients: A Real-World Analysis (TCT-ASTCT-CIBMTR 2026) - "Results : In our real-world cohort (N=90), 31 (34.4%) received ABECMA and 59 (65.6%) CARVYKTI...All affected patients received CARVYKTI following Fludarabine/Cytoxan lymphodepleting therapy...Our approach includes bridging therapy to reduce disease burden prior to CAR-T infusion and brief dexamethasone treatment for unrestrained lymphocyte expansion measured by ALC...3. To evaluate real-world outcomes and current management approaches for CAR-T-related neurotoxicity."

Clinical • Real-world • Real-world evidence • CNS Disorders • Hematological Malignancies • Movement Disorders • Multiple Myeloma • Parkinson's Disease

Geographic Distribution and Racial Disparities of CAR-T cell Therapy Centers in the United States (TCT-ASTCT-CIBMTR 2026) - "Product availability varied: tisa-cel was offered at 118 centers, axi-cel and brexu-cel at 160 each, ide-cel and liso- cel at 159 each, cilta-cel at 125, and obe-cel at 53... Although CAR-T centers are distributed nationwide, per-capita access remains limited, particularly in large, minority-dense states. Regions with substantial Hispanic and AA populations demonstrate underrepresentation in CAR-T therapy access relative to their population size, highlighting the need to expand treatment infrastructure to reduce racial and geographic disparities in CAR-T availability. 1."

CAR T-Cell Therapy • Hematological Malignancies

Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients (TCT-ASTCT-CIBMTR 2026) - "Cilta-cel and ide-cel recipients had comparable baseline demographics but differed in socioeconomic factors and disease variables. Our data highlights the importance of continuing to address SDOH to ensure equitable delivery of cellular therapies. Social Determinants of Health, CAR-T Therapy, Autologous stem cell transplant"

Clinical • Hematological Malignancies • Multiple Myeloma

Mapping Gaps: Geographic and Racial Disparities in CAR-T cell Therapy Access for Multiple Myeloma and B-ALL in the United States (TCT-ASTCT-CIBMTR 2026) - "Obe-cel, Tisa-cel and Cilta-cel remained less widely distributed compared to Ide-cel, Axi-cel and Liso-cel, and were absent in multiple states (Obe-cel was not available in 27 states, Tisa-cel in 11 and Cilta-cel in 8). Significant racial inequities exist in CAR-T access for both MM and B-ALL. African Americans have limited availability of anti-BCMA therapies (Ide-cel, Cilta-cel) in high-AA states, while Hispanics face similarly restricted access to B-ALL products (Tisa-cel, Brexu-cel, Obe-cel) in Hispanic-dense regions. Targeted expansion of CAR-T centers is critical to achieving equitable access for these high-burden populations."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma

The Relationship of Social Support and Psychosocial Complexity with Chimeric Antigen Receptor T-cell Therapy Outcomes (TCT-ASTCT-CIBMTR 2026) - "A plurality of patients received liso-cel (29%), followed by tisa-cel (19%), axi-cel (18%), and ide-cel (13%). In a systematic social support analysis, a significant percentage of patients noted caregiver availability issues and/or financial concerns. However, neither LSS nor IPC were associated with increased CAR-T toxicity or worse survival, underscoring that psychosocial barriers should not limit access to CAR-T. - Identify psychosocial and caregiver challenges among CAR-T recipients - Assess associations between social support, psychosocial complexity, and CAR-T outcomes - Recognize implications of psychosocial factors for equitable CAR-T access"

CAR T-Cell Therapy • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma